Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MeiraGTx UK II Ltd
A dose escalation and dose expansion (Phase I/II) trial of adults and children with retinal dystrophy associated with defects in RPE65. ATIMP will be administered to one eye only in a single sub-retinal procedure
Age
3–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 3 years or older
Early-onset severe retinal dystrophy consistent with RPE65 deficiency
You may not be if
Females who are pregnant or breastfeeding
Have participated in another research study involving an investigational therapy for ocular disease within the last 6 months.
